TP53 mutations, although not yet directly targetable, are reported in up to 30% of UTUC cases, particularly in high-grade tumors with increased genomic instability, and are associated with more aggressive disease and poorer clinical outcomes (Figure 1). This evidence concerns the gene TP53 and renal pelvis/ureter urothelial carcinoma.